| Inbound Relationships |
Type |
Active |
Source |
Characteristic |
Refinability |
Group |
| Product containing phenyltoloxamine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| Product containing clemastine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| Product containing calcium channel blocker (product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| klasse I-antiarytmikum |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| klasse Ia-antiarytmikum |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| Product containing alpha adrenergic receptor antagonist (product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| antiarytmikum |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| klasse II-antiarytmikum |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| Product containing bromazine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| Product containing alpha-1 adrenergic receptor antagonist (product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| klasse III-antiarytmikum |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| klasse Ib-antiarytmikum |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| Product containing diphenylpyraline (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| klasse Ic-antiarytmikum |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| Product containing carbinoxamine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| clemastinfumarat + phenylpropanolaminhydrochlorid + paracetamol |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| Product containing precisely clemastine fumarate 335 microgram and paracetamol 500 milligram and phenylpropanolamine 30 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| Product containing precisely trimethobenzamide hydrochloride 300 milligram/1 each conventional release oral capsule (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| Adverse reaction to drug primarily affecting the cardiovascular system NOS |
Causative agent |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| Individual arrhythmias [no drugs here] |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| Drug for supraventricular arrhythmia |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| Drug for ventricular arrhythmia |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| Diphenylpyraline hydrochloride |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| Product containing magnesium salicylate and phenyltoloxamine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| ethanolaminoleat 5 % injektionsvæske, opløsning, 2 ml ampul |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| ethanolaminoleat 5 % injektionsvæske, opløsning, 5 ml ampul |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| trimethobenzamidhydrochlorid |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| Cardiac adrenergic blocking product |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| Anesthetic antiarrhythmic agent |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| bromazin + codein 12,5 mg/5 ml/10 mg/5ml syrup |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| carbinoxaminmaleat 4 mg/5 ml + dextromethorphanhydrobromid 15 mg/5 ml + pseudoephedrinhydrochlorid 60 mg/5 ml syrup |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| carbinoxaminmaleat + dextromethorphanhydrobromid + pseudoephedrinhydrochlorid 2 mg/1 ml/4 mg/1 ml/25 mg/1 ml væske |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| carbinoxaminmaleat 2 mg/1 ml + dextromethorphanhydrobromid 4 mg/1 ml + pseudoephedrinhydrochlorid 15 mg/1 ml væske |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| carbinoxaminmaleat + pseudoephedrinhydrochlorid 4 mg/5 ml/60 mg/5 ml væske |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| carbinoxaminmaleat 2 mg/1 ml + pseudoephedrinhydrochlorid 15 mg/1 ml væske |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| carbinoxaminmaleat + pseudoephedrinhydrochlorid 2 mg/1 ml/25 mg/1 ml væske |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| carbinoxaminmaleat 2 mg/5 ml + pseudoephedrinhydrochlorid 30 mg/5 ml væske |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| Carbinoxamine maleate 4 mg and pseudoephedrine hydrochloride 60 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| Carbinoxamine maleate 4 mg and pseudoephedrine hydrochloride 60 mg chewable tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| carbinoxaminmaleat + pseudoephedrinhydrochlorid 8 mg/120 mg tablet med modificeret udløsning |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| clemastinfumarat 0,67 mg/5 ml syrup |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| Clemastine fumarate 2.68 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| ethanolaminoleat 50 mg/ml injektionsvæske, 2 ml ampul |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| chlorpheniraminmaleat 4 mg + phenylephrinhydrochlorid 20 mg + phenyltoloxamincitrat 50 mg kapsel med modificeret udløsning |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| chlorpheniraminmaleat + phenylephrinhydrochlorid + phenyltoloxamincitrat 2,5 mg/5 ml 5 mg/5 ml 7,5 mg/5 ml væske |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| Product containing precisely trimethobenzamide hydrochloride 250 milligram/1 each conventional release oral capsule (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| Product containing precisely trimethobenzamide hydrochloride 100 milligram/1 each conventional release oral capsule (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| trimethobenzamidhydrochlorid 100 mg/2 % suppositorium |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| trimethobenzamidhydrochlorid 200 mg/2 % suppositorium |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| trimethobenzamidhydrochlorid 100 mg/ml opløsning til intramuskulær anvendelse |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| carbinoxaminmaleat 2 mg/5 ml væske |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| trimethobenzamidhydrochlorid 100 mg/ml injektionsvæske, opløsning, ampul |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| trimethobenzamidhydrochlorid 200 mg suppositorium |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| trimethobenzamidhydrochlorid 100 mg |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| Trimethobenzamide hydrochloride 100mg/mL bar |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| Nonspecific alpha-adrenergic blocking product |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| Product containing precisely paracetamol 300 milligram and phenyltoloxamine citrate 20 milligram and salicylamide 200 milligram/1 each conventional release oral capsule (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| Paracetamol 300 mg and phenyltoloxamine citrate 20 mg and salicylamide 200 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| paracetamol 500 mg + phenyltoloxamincitrat 30 mg kapselformede tabletter |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| Paracetamol 500 mg and phenyltoloxamine citrate 50 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| Paracetamol 500 mg and phenyltoloxamine citrate 60 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| Paracetamol 650 mg and phenyltoloxamine citrate 50 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| benzocain 2% wt/wt + trimethobenzamidhydrochlorid 100 mg suppositorier |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| Benzocaine 20 microgram and trimethobenzamide hydrochloride 200 mg rectal suppository |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| Product containing precisely clemastine 1.34 milligram and phenylpropanolamine 75 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| carbinoxaminmaleat + dextromethorphanhydrobromid + pseudoephedrinhydrochlorid 4 mg/5 ml/12,5 mg/5 ml/60 mg/5 ml syrup |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| carbinoxaminmaleat + dextromethorphanhydrobromid + pseudoephedrinhydrochlorid 1 mg/1 ml/4 mg/1 ml/15 mg/1 ml dråber |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| carbinoxaminmaleat + pseudoephedrinhydrochlorid 1 mg/1 ml/15 mg/1 ml dråber |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| [X]Lipid-lowering drug adverse reaction |
Causative agent |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| [X]Statin causing adverse effect in therapeutic use |
Causative agent |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| paracetamol + phenyltoloxamincitrat |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| carbinoxaminmaleat + dextromethorphanhydrobromid + pseudoephedrinhydrochlorid |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| benzocain + trimethobenzamidhydrochlorid |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| chlorpheniraminmaleat + phenylephrinhydrochlorid + phenyltoloxamincitrat |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| paracetamol + phenyltoloxamincitrat + salicylamid |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| Product containing bromazine and codeine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| carbinoxaminmaleat + pseudoephedrinhydrochlorid |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| [X]Angiotensin II receptor antagonists causing adverse effects in therapeutic use |
Causative agent |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| clemastin 1,34 mg tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| Adenosine A2 receptor agonist |
Is a |
True |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| Cardioversion using medication (procedure) |
Using substance (attribute) |
True |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
1 |
| allergi over for lægemidler med primær effekt på det kardiovaskulære system |
Causative agent |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
1 |
| Spironolactone adverse reaction |
Causative agent |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
2 |
| bivirkning af diuretikum indeholdende spironolacton og thiazid |
Causative agent |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
3 |
| Cyclopenthiazide adverse reaction |
Causative agent |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
2 |
| Intentional furosemide poisoning |
Causative agent |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
1 |
| Allergy to mersalyl |
Causative agent |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
2 |
| Accidental acetazolamide poisoning |
Causative agent |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
1 |
| Allergy to hydrochlorothiazide |
Causative agent |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
2 |
| forgiftning med diuretikum |
Causative agent |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
2 |
| Allergy to triamterene |
Causative agent |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
2 |
| allergi over for diuretikum indeholdende amilorid og thiazid |
Causative agent |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
3 |
| Allergy to piretanide (finding) |
Causative agent |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
2 |
| bivirkning af amilorid og loop-diuretikum |
Causative agent |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
3 |
| Mannitol adverse reaction |
Causative agent |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
2 |
| Mefruside adverse reaction |
Causative agent |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
2 |
| Allergy to acetazolamide (finding) |
Causative agent |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
2 |
| Poisoning by acetazolamide |
Causative agent |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
2 |
| forgiftning med furosemid, uvist med hvilken hensigt |
Causative agent |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
2 |
| Mercaptomerin poisoning |
Causative agent |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
2 |
| Indapamide adverse reaction (disorder) |
Causative agent |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
2 |
FHIR